February 23, 2021
Generally, guidelines recommend beginning psoriatic arthritis (PsA) treatment with tumor necrosis factor inhibitors (TNFis). However, not all patients respond to this method. Ixekizumab (IXE) improved the signs and symptoms of PsA in patients who had exhibited inadequate response to 1 or 2 TNFis.
February 17, 2021
The drug is commonly used to treat diseases such as psoriatic arthritis, Behcet’s Syndrome, and plaque psoriasis.
February 05, 2021
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
January 27, 2021
Investigators determined, “Treatment with TNF inhibitors is not associated with increased risks of solid cancer overall, or eight common cancer types. There were no indications of different crude incidence of solid cancers overall by TNF inhibitor agent.”
January 25, 2021
Alyssa Johnsen, MD, PhD, shares her insight on the importance of understanding key pathways that drive immune-mediated diseases, which can help rheumatologists develop more potent and specific therapies for patients with rheumatic disease.
January 21, 2021
Improvement in ASAS20 (Assessment of SpondyloArthritis international Society) was seen in 63% of participants assigned to secukinumab 300 mg and 66% of those assigned to secukinumab 150 mg, versus 31% of the placebo group.
December 23, 2020
Some of the latest developments in the use of these diagnostic tools for psoriatic arthritis were presented the annual meeting of the American College of Rheumatology Convergence 2020 in November.
December 14, 2020
Patients who had received tofacitinib combination therapy may be able to discontinue methotrexate.
November 24, 2020
More than half of patients with psoriatic arthritis have to wait two or more years for a diagnosis, researchers report.
November 24, 2020
Many patients with psoriatic arthritis live with unacceptable levels of disease activity despite treatment, and patient-reported outcomes could provide useful treatment targets, shows a new study.